Product Information
FR167344 is a b2 receptor antagonist that inhibits the binding of the ligands bradykinin and thromboxane A2 to their receptors. It has been shown to be effective in the treatment of inflammatory diseases such as pancreatitis, and also for reducing leukotriene synthesis. The pharmacokinetics of FR167344 have been studied in rats, mice, and healthy volunteers. It is absorbed from the gastrointestinal tract and eliminated by liver metabolism. The drug is eliminated mainly through renal excretion of unchanged drug, with less than 1% metabolized by the liver.
FR167344 has been shown to inhibit binding of bradykinin to its receptor in cell membrane preparations from human epidermoid carcinoma (A431) cells and lung fibroblasts, with a maximal response at concentrations between 0.1-10 µM.
Chemical properties
Technical inquiry about: FR167344
Please use instead the cart to request a quotation or an order